APO RESEARCH · REPORT
Dry Powder Inhaler Device
A dry powder inhaler (DPI) is a device that delivers medication to the lungs in the form of a dry powder. DPIs are commonly used to treat respiratory diseases such as asthma, bronchitis, emphysema and COPD although DPIs (such as inhalable insulin Afrezza) have also been used in the treatment of diabetes mellitus.
Product & engineering
Understand the product.
A dry powder inhaler (DPI) is a device that delivers medication to the lungs in the form of a dry powder. DPIs are commonly used to treat respiratory diseases such as asthma, bronchitis, emphysema and COPD although DPIs (such as inhalable insulin Afrezza) have also been used in the treatment of diabetes mellitus.
Selected research
Industry Research
Dry Powder Inhaler Device Industry Research Report 2026
Market perspective
A dry powder inhaler (DPI) is a device that delivers medication to the lungs in the form of a dry powder. DPIs are commonly used to treat respiratory diseases such as asthma, bronchitis, emphysema and COPD although DPIs (such as inhalable insulin Afrezza) have also been used in the treatment of diabetes mellitus.
GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Chiesi, etc. are the key players in the global Dry Powder Inhaler Device market. Top 4 took up more than 30% of the global market.
From the view of region, USA have a larger consumption market share which account for about 35% of total share. Europe hold a market share of about 25%. In addition, Asia Pacific is also play important role in Global market.
Read the full market overview
Dry Powder Inhaler Device main application area is Asthma This sector hold a market share of over 80%. Then followed by the COPD.
According to the Segmentation of types, all the market of Dry Powder Inhaler Device can be divided as follows: Multi-dose, Single-dose.
Report Scope
This report quantifies the global Dry Powder Inhaler Device market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Dry Powder Inhaler Device Market by Company
GlaxoSmithKline
AstraZeneca
Boehringer Ingelheim
Chiesi
Cipla
3M
Hovione
Mannkind
Mylan
Novartis
Schering/Merck
Teva
Vectura
Dry Powder Inhaler Device Segment by Type
Single Dose
Multi Dose
Dry Powder Inhaler Device Segment by Application
Asthma
COPD
Others
Dry Powder Inhaler Device Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dry Powder Inhaler Device market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Dry Powder Inhaler Device and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dry Powder Inhaler Device.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Dry Powder Inhaler Device manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Dry Powder Inhaler Device by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Dry Powder Inhaler Device in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Single Dose
- Multi Dose
Applications
- Asthma
- COPD
- Others
Companies covered
- GlaxoSmithKline
- AstraZeneca
- Boehringer Ingelheim
- Chiesi
- Cipla
- 3M
- Hovione
- Mannkind
- Mylan
- Novartis
- Schering/Merck
- Teva
- Vectura
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Dry Powder Inhaler Device Market Size (2021-2032)
- 2.2.2 Global Dry Powder Inhaler Device Sales (2021-2032)
- 2.2.3 Global Dry Powder Inhaler Device Market Average Price (2021-2032)
- 2.3 Dry Powder Inhaler Device by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Single Dose
- 2.3.3 Multi Dose
- 2.4 Dry Powder Inhaler Device by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Asthma
- 2.4.3 COPD
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Dry Powder Inhaler Device Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Dry Powder Inhaler Device Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Dry Powder Inhaler Device Revenue of Manufacturers (2021-2026)
- 3.4 Global Dry Powder Inhaler Device Average Price by Manufacturers (2021-2026)
- 3.5 Global Dry Powder Inhaler Device Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Dry Powder Inhaler Device, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Dry Powder Inhaler Device, Product Type & Application
- 3.8 Global Manufacturers of Dry Powder Inhaler Device, Established Date
- 3.9 Global Dry Powder Inhaler Device Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 GlaxoSmithKline
- 4.1.1 GlaxoSmithKline Company Information
- 4.1.2 GlaxoSmithKline Business Overview
- 4.1.3 GlaxoSmithKline Dry Powder Inhaler Device Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 GlaxoSmithKline Dry Powder Inhaler Device Product Portfolio
- 4.1.5 GlaxoSmithKline Recent Developments
- 4.2 AstraZeneca
- 4.2.1 AstraZeneca Company Information
- 4.2.2 AstraZeneca Business Overview
- 4.2.3 AstraZeneca Dry Powder Inhaler Device Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 AstraZeneca Dry Powder Inhaler Device Product Portfolio
- 4.2.5 AstraZeneca Recent Developments
- 4.3 Boehringer Ingelheim
- 4.3.1 Boehringer Ingelheim Company Information
- 4.3.2 Boehringer Ingelheim Business Overview
- 4.3.3 Boehringer Ingelheim Dry Powder Inhaler Device Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Boehringer Ingelheim Dry Powder Inhaler Device Product Portfolio
- 4.3.5 Boehringer Ingelheim Recent Developments
- 4.4 Chiesi
- 4.4.1 Chiesi Company Information
- 4.4.2 Chiesi Business Overview
- 4.4.3 Chiesi Dry Powder Inhaler Device Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Chiesi Dry Powder Inhaler Device Product Portfolio
- 4.4.5 Chiesi Recent Developments
- 4.5 Cipla
- 4.5.1 Cipla Company Information
- 4.5.2 Cipla Business Overview
- 4.5.3 Cipla Dry Powder Inhaler Device Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Cipla Dry Powder Inhaler Device Product Portfolio
- 4.5.5 Cipla Recent Developments
- 4.6 3M
- 4.6.1 3M Company Information
- 4.6.2 3M Business Overview
- 4.6.3 3M Dry Powder Inhaler Device Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 3M Dry Powder Inhaler Device Product Portfolio
- 4.6.5 3M Recent Developments
- 4.7 Hovione
- 4.7.1 Hovione Company Information
- 4.7.2 Hovione Business Overview
- 4.7.3 Hovione Dry Powder Inhaler Device Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Hovione Dry Powder Inhaler Device Product Portfolio
- 4.7.5 Hovione Recent Developments
- 4.8 Mannkind
- 4.8.1 Mannkind Company Information
- 4.8.2 Mannkind Business Overview
- 4.8.3 Mannkind Dry Powder Inhaler Device Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Mannkind Dry Powder Inhaler Device Product Portfolio
- 4.8.5 Mannkind Recent Developments
- 4.9 Mylan
- 4.9.1 Mylan Company Information
- 4.9.2 Mylan Business Overview
- 4.9.3 Mylan Dry Powder Inhaler Device Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Mylan Dry Powder Inhaler Device Product Portfolio
- 4.9.5 Mylan Recent Developments
- 4.10 Novartis
- 4.10.1 Novartis Company Information
- 4.10.2 Novartis Business Overview
- 4.10.3 Novartis Dry Powder Inhaler Device Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Novartis Dry Powder Inhaler Device Product Portfolio
- 4.10.5 Novartis Recent Developments
- 4.11 Schering/Merck
- 4.11.1 Schering/Merck Company Information
- 4.11.2 Schering/Merck Business Overview
- 4.11.3 Schering/Merck Dry Powder Inhaler Device Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Schering/Merck Dry Powder Inhaler Device Product Portfolio
- 4.11.5 Schering/Merck Recent Developments
- 4.12 Teva
- 4.12.1 Teva Company Information
- 4.12.2 Teva Business Overview
- 4.12.3 Teva Dry Powder Inhaler Device Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Teva Dry Powder Inhaler Device Product Portfolio
- 4.12.5 Teva Recent Developments
- 4.13 Vectura
- 4.13.1 Vectura Company Information
- 4.13.2 Vectura Business Overview
- 4.13.3 Vectura Dry Powder Inhaler Device Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Vectura Dry Powder Inhaler Device Product Portfolio
- 4.13.5 Vectura Recent Developments
5 Global Dry Powder Inhaler Device Market Scenario by Region
- 5.1 Global Dry Powder Inhaler Device Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Dry Powder Inhaler Device Sales by Region: 2021-2032
- 5.2.1 Global Dry Powder Inhaler Device Sales by Region: 2021-2026
- 5.2.2 Global Dry Powder Inhaler Device Sales by Region: 2027-2032
- 5.3 Global Dry Powder Inhaler Device Revenue by Region: 2021-2032
- 5.3.1 Global Dry Powder Inhaler Device Revenue by Region: 2021-2026
- 5.3.2 Global Dry Powder Inhaler Device Revenue by Region: 2027-2032
- 5.4 North America Dry Powder Inhaler Device Market Facts & Figures by Country
- 5.4.1 North America Dry Powder Inhaler Device Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Dry Powder Inhaler Device Sales by Country (2021-2032)
- 5.4.3 North America Dry Powder Inhaler Device Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Dry Powder Inhaler Device Market Facts & Figures by Country
- 5.5.1 Europe Dry Powder Inhaler Device Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Dry Powder Inhaler Device Sales by Country (2021-2032)
- 5.5.3 Europe Dry Powder Inhaler Device Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Dry Powder Inhaler Device Market Facts & Figures by Country
- 5.6.1 Asia Pacific Dry Powder Inhaler Device Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Dry Powder Inhaler Device Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Dry Powder Inhaler Device Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Dry Powder Inhaler Device Market Facts & Figures by Country
- 5.7.1 South America Dry Powder Inhaler Device Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Dry Powder Inhaler Device Sales by Country (2021-2032)
- 5.7.3 South America Dry Powder Inhaler Device Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Dry Powder Inhaler Device Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Dry Powder Inhaler Device Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Dry Powder Inhaler Device Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Dry Powder Inhaler Device Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Dry Powder Inhaler Device Sales by Type (2021-2032)
- 6.1.1 Global Dry Powder Inhaler Device Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Dry Powder Inhaler Device Sales Market Share by Type (2021-2032)
- 6.2 Global Dry Powder Inhaler Device Revenue by Type (2021-2032)
- 6.2.1 Global Dry Powder Inhaler Device Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Dry Powder Inhaler Device Revenue Market Share by Type (2021-2032)
- 6.3 Global Dry Powder Inhaler Device Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Dry Powder Inhaler Device Sales by Application (2021-2032)
- 7.1.1 Global Dry Powder Inhaler Device Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Dry Powder Inhaler Device Sales Market Share by Application (2021-2032)
- 7.2 Global Dry Powder Inhaler Device Revenue by Application (2021-2032)
- 7.2.1 Global Dry Powder Inhaler Device Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Dry Powder Inhaler Device Revenue Market Share by Application (2021-2032)
- 7.3 Global Dry Powder Inhaler Device Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Dry Powder Inhaler Device Value Chain Analysis
- 8.1.1 Dry Powder Inhaler Device Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Dry Powder Inhaler Device Production Mode & Process
- 8.2 Dry Powder Inhaler Device Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Dry Powder Inhaler Device Distributors
- 8.2.3 Dry Powder Inhaler Device Customers
9 Global Dry Powder Inhaler Device Analyzing Market Dynamics
- 9.1 Dry Powder Inhaler Device Industry Trends
- 9.2 Dry Powder Inhaler Device Industry Drivers
- 9.3 Dry Powder Inhaler Device Industry Opportunities and Challenges
- 9.4 Dry Powder Inhaler Device Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst